Blood clot fears halt cancer trial enrolment

pharmafile | February 3, 2011 | News story | Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer 

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung cancer.

New enrolment to the INSPIRE trial was stopped after an independent Data Monitoring Committee (DMC) detected a raised risk of blood clots in patients receiving the drug.

Necitumumab is a fully-human IgG1 monoclonal antibody and the INSPIRE trial is investigating its use in combination with Alimta (pemetrexed) and cisplatin compared to a regimen of Alimta and cisplatin, as a first-line treatment for patients with advanced non-squamous NSCLC. No new safety issues were seen in the control arm with Alimta and cisplatin.

Patients who have already received two or more cycles of necitumumab appear to have a lower ongoing risk of clots, and these patients may choose to remain on the trial, after being informed of the additional potential risks. Investigators will continue to assess patients after two cycles to determine if there is a potential benefit from treatment.

The drug will continue to be studied in a parallel phase III trial named SQUIRE, which is investigating its use in squamous rather than non-squamous non-small cell lung cancer. In this trial, the drug is being combined with Gemzar (gemcitabine) and cisplatin. The DMC says this trial can continue because no safety concerns have been observed.

“Patient safety is paramount. While stopping enrolment in one of the two phase III trials is disappointing, the SQUIRE phase III study of necitumumab in lung cancer continues,” said Richard Gaynor, vice president, oncology product development and medical affairs for Lilly. “Lilly remains committed to developing new medicines that can help treat this devastating disease.”

Andrew McConaghie

Related Content

Eli Lilly shares results for tirzepatide for MASH resolution

Eli Lilly has announced results from the phase 2 SYNERGY-NASH study which assessed 190 patients, …

Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases

Eli Lilly has announced that it will donate $6.5m to the United States Fund for …

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …

Latest content